Loading…
Immatics N.V. is projected to rise to $12.72 by 2027, a +31% move from its current price of $9.68. IMTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $9.44 | $9.68 | $9.93 | +0.03% |
| Jul 15 | $9.35 | $9.69 | $10.03 | +0.06% |
| Jul 16 | $9.28 | $9.69 | $10.12 | +0.08% |
| Jul 17 | $9.22 | $9.69 | $10.19 | +0.11% |
| Jul 18 | $9.17 | $9.69 | $10.25 | +0.14% |
| Jul 19 | $9.12 | $9.70 | $10.31 | +0.17% |
| Jul 20 | $9.08 | $9.70 | $10.36 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.08 | $9.70 | $10.36 | +0.19% |
| Week 2 | $8.85 | $9.72 | $10.67 | +0.39% |
| Week 3 | $8.69 | $9.74 | $10.91 | +0.58% |
| Week 4 | $8.55 | $9.75 | $11.13 | +0.77% |
| Week 5 | $8.43 | $9.77 | $11.33 | +0.97% |
| Week 6 | $8.33 | $9.79 | $11.51 | +1.16% |
| Week 7 | $8.24 | $9.81 | $11.68 | +1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immatics N.V. is a clinical-stage biopharmaceutical company focused on research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. It develops targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Its pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
Immatics N.V. is headquartered in Tübingen, Germany.
Immatics N.V. (IMTX) operates in the Healthcare sector with a current price of $9.91 and a market capitalization of $1.35B. It is ranked 2326 in market listings.
The stock’s near-term technical setup shows a bullish tilt, with a 30-day range that reflects modest volatility and an RSI of 50. The stock sits around key moving averages, with a SMA50 of $10.68 and a SMA200 of $9.85, suggesting a tug between resistance and support around those levels.
The 30-day price range spans $8.27 to $11.87, with a defined support at $8.87 and a resistance at $11.62. The stock exhibits an annualized volatility of 50% and a bullish technical backdrop alongside a bullish sentiment in the near term. Forecasts project a long-term upside, with a path that lifts the average price from current levels toward higher targets, including an average of $65.11 and a max of $120.60 by 2050, alongside a multi-decade upward tilt with corresponding ROI figures.
A major floor 23.8% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 18.9% above — a clean break opens room to run.
A major ceiling 30.8% above — clearing it would confirm fresh momentum.
Key IMTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.97 | Sell | $9.89 | Sell |
| MA 10 | $9.89 | Sell | $9.88 | Sell |
| MA 20 | $9.72 | Sell | $9.90 | Sell |
| MA 50 | $10.37 | Sell | $10.12 | Sell |
| MA 100 | $10.31 | Sell | $10.13 | Sell |
| MA 200 | $10.07 | Sell | $9.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.27 | Neutral |
| Stoch RSI (14) | 21.23 | Neutral |
| CCI (20) | -9.55 | Neutral |
| Williams %R (14) | -78.38 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | -2.32 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 21.62 | Neutral |
| TRIX (15) | -0.23 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 37.51 | Neutral |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 9.96 | Sell |
| ADX (14) | 10.64 | Neutral |
| ATR (14) | 0.23 | Info |
The 30-day technical picture shows a bullish tilt, with RSI14 at 50. The stock trades near the SMA50 of $10.68 and the SMA200 of $9.85, suggesting near-term momentum around those levels.
Key near-term support is at $8.87 and resistance at $11.62, framing a 30-day range of $8.27 to $11.87. The volatility profile is notable, with an annualized volatility of 50% shaping risk considerations in the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.57 | $9.68 | $12.58 | 0% | Neutral | |
| $10.21 | $12.72 | $16.71 | +31% | Bullish | |
| $10.99 | $14.04 | $19.09 | +45% | Bullish | |
| $11.84 | $15.45 | $21.58 | +60% | Bullish | |
| $12.31 | $16.35 | $23.36 | +69% | Bullish | |
| $12.13 | $16.39 | $23.88 | +69% | Bullish | |
| $13.36 | $18.34 | $27.20 | +89% | Bullish | |
| $15.92 | $22.17 | $33.41 | +129% | Bullish | |
| $17.84 | $25.19 | $38.52 | +160% | Bullish | |
| $18.12 | $25.93 | $40.20 | +168% | Bullish | |
| $26.32 | $39.95 | $65.64 | +313% | Bullish | |
| $38.41 | $64.52 | $115.35 | +567% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.57 | $9.68 | $11.63 | +0.00% |
| August 2026 | $8.25 | $9.71 | $11.72 | +0.32% |
| September 2026 | $8.38 | $9.93 | $12.11 | +2.22% |
| October 2026 | $8.66 | $10.32 | $12.70 | +3.97% |
| November 2026 | $8.58 | $10.27 | $12.73 | -0.45% |
| December 2026 | $8.39 | $10.08 | $12.58 | -1.85% |
Click any year to see its month-by-month IMTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IMTX price prediction for 2026 points to an average of $9.68 (low $8.57, high $12.58) — a potential gain of 0% on today's $9.68. A consolidation phase looks the most probable path here.
In 2027, IMTX is projected to trade between $10.21 and $16.71, averaging $12.72 — a potential gain of +31% from today's $9.68. That is up +31% on the projected 2026 average. Momentum favours further upside here.
Immatics N.V.'s 2028 outlook centres on $14.04, within a $10.99 to $19.09 range. That is up +10% on the projected 2027 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, IMTX could reach as high as $21.58, with a base case around $15.45 and support toward $11.84 — roughly +60% from $9.68. Momentum favours further upside here.
Expect IMTX to range from $12.31 to $23.36 through 2030. The $16.35 average target implies a +69% move from current prices. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The IMTX price prediction for 2031 points to an average of $16.39 (low $12.13, high $23.88) — a potential gain of +69% on today's $9.68. Momentum favours further upside here.
In 2032, IMTX is projected to trade between $13.36 and $27.20, averaging $18.34 — a potential gain of +89% from today's $9.68. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Immatics N.V.'s 2033 outlook centres on $22.17, within a $15.92 to $33.41 range. That is up +21% on the projected 2032 average. That marks a +129% change versus current levels. Momentum favours further upside here.
By 2034, IMTX could reach as high as $38.52, with a base case around $25.19 and support toward $17.84 — roughly +160% from $9.68. Buyers look set to stay in control over this stretch.
Expect IMTX to range from $18.12 to $40.20 through 2035. The $25.93 average target implies a +168% move from current prices. That is up +3% on the projected 2034 average. Momentum favours further upside here.
The IMTX price prediction for 2040 points to an average of $39.95 (low $26.32, high $65.64) — a potential gain of +313% on today's $9.68. Buyers look set to stay in control over this stretch.
In 2050, IMTX is projected to trade between $38.41 and $115.35, averaging $64.52 — a potential gain of +567% from today's $9.68. That is up +61% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IMTX today (≈ 103.305785 IMTX) could be worth
$6,664.96
+$5,664.96 (+566%) by 2050 · US Dollar
Based on the average projected IMTX price of $64.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMTXwould be worth at today's price.
$1,000 invested in IMTX on Jul 10, 2025 (≈ 166.666667 IMTX) would be worth
$1,613.33
+$613.33 (+61.3%) today · 1.61× · US Dollar
Based on a IMTX entry price of $6 vs. today's $9.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.95 | $972.86 | -2.7% |
| 1 month ago | $8.87 | $1,091.32 | +9.1% |
| 3 months ago | $10.43 | $928.09 | -7.2% |
| 6 months ago | $9.16 | $1,056.77 | +5.7% |
| 1 year ago | $6 | $1,613.33 | +61.3% |
| All time (5.0y) ago | $12.09 | $800.66 | -19.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMTX forecast.
Our base-case forecast reaches $19.00 around 2033.
Implied market cap at $19.00: $2.6B
The multi-year forecast indicates a bullish trajectory across the horizon. In 2026, the avg price is $9.91 with a min of $8.57 and a max of $13.08, yielding a 0% ROI and a neutral sentiment. From 2027 onward, the outlook strengthens: avg prices rise to $13.35 (ROI 34.7%, bullish) and to $14.37 (ROI 45%, bullish) in 2028, and to $16.05 (ROI 61.9%, bullish) in 2029.
By 2030, the average is projected at $16.88 with a min of $12.49 and a max of $24.60, delivering a 70.3% ROI and a bullish sentiment. The path continues higher through 2031–2035, with 2032 avg $19.01 (ROI 91.8%), 2033 avg $23.16 (ROI 133.7%), 2034 avg $25.29 (ROI 155.2%), and 2035 avg $26.78 (ROI 170.3%), all bullish.
In 2040, the avg price is forecast at $40.59 (max $68.70; ROI 309.5%), and by 2050 the avg rises to $65.11 (max $120.60; ROI 557%), with sentiment remaining bullish. These projections illustrate a long-run upside but remain estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $16.88, a min of $12.49 and a max of $24.60, with ROI of 70.3% and bullish sentiment.
The forecast turns from neutral in 2026 (avg $9.91) to bullish from 2027 onward (averages rising to $13.35 in 2027, $14.37 in 2028, $16.05 in 2029, $16.88 in 2030, etc.), with increasing ROI through 2050; these are estimates, not guarantees.
Yes—the 2050 max forecast is $120.60, with an average of $65.11 and a 557% ROI; sentiment is bullish.
Current price is $9.91 and market cap is $1.35B.
The 30-day range is $8.27 to $11.87.
Immatics N.V. Community Discussion
0Share your Immatics N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.